Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIN1 | Q13526 | 13/20 | 0.65 |
| ▸ | GLO1 | Q04760 | 2/20 | 0.47 |
| ▸ | GSK3B | P49841 | 1/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | MET | P08581 | 1/20 | 0.41 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.41 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29190534 | 0.83 | GLO1 (0.51) | PIN1GLO1PTGS1PTGS2MET | |
| SCHEMBL29435445 | 0.82 | ALK (0.54) | PIN1GLO1PTGS1PTGS2MET | |
| SCHEMBL542158 | 0.82 | ALK (0.54) | PIN1GLO1PTGS1PTGS2MET | |
| SCHEMBL375418 | 0.81 | PIN1 (0.59) | PIN1GSK3BMEN1KMT2AMET | |
| SCHEMBL1076995 | 0.81 | GLO1 (0.52) | PIN1GLO1PTGS1PTGS2MET | |
| SCHEMBL30942610 | 0.81 | GLO1 (0.52) | PIN1GLO1PTGS1PTGS2MET | |
| SCHEMBL600898 | 0.80 | GLO1 (0.51) | PIN1GLO1PTGS1PTGS2MEN1 | |
| SCHEMBL30942603 | 0.80 | GLO1 (0.69) | PIN1GLO1PTGS1PTGS2MET | |
| SCHEMBL542074 | 0.80 | GLO1 (0.69) | PIN1GLO1PTGS1PTGS2MET | |
| SCHEMBL18181774 | 0.80 | PIN1 (0.63) | PIN1GSK3BMEN1KMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110098288-A1 | SULFONAMIDES AS ZAP-70 INHIBITORS | CELLZOME LIMITED (GB) | 2011-04-28 | — | — | US | disclosed |
| EP-2276747-A1 | SULFONAMIDES AS ZAP-70 INHIBITORS | Cellzome Limited (GB) | 2011-01-26 | — | — | EP | disclosed |
| WO-2009112490-A1 | SULFONAMIDES AS ZAP-70 INHIBITORS | CELLZOME LIMITED (GB) | 2009-09-17 | — | — | WO | disclosed |
| WO-2009112490-A1 | SULFONAMIDES AS ZAP-70 INHIBITORS | CELLZOME LIMITED (GB) | 2009-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098288-A1 | SULFONAMIDES AS ZAP-70 INHIBITORS | ZAP70, SYK, LCK | PIN1 1088/4885GLO1 3741/4885GSK3B 2263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.